Menopausal Symptom Burden Tied to Cognitive, Behavioral Impairment
By Lori Solomon HealthDay Reporter
MONDAY, March 17, 2025 -- Higher menopausal symptom burden is associated with poorer cognitive and behavioral impairment later in life, according to a study published online March 5 in PLOS ONE.
Jasper F.E. Crockford, from the University of Calgary in Alberta, Canada, and colleagues investigated the association between menopausal symptoms and cognitive and behavioral changes. Analysis included 896 postmenopausal female participants.
The researchers found that greater menopausal symptom burden was associated with higher Everyday Cognition (ECog-II) Scale total scores (b = 5.37; 95 percent confidence interval, 2.85 to 7.97) and higher Mild Behavioral Impairment Checklist (MBI-C) total scores (b = 6.09; 95 percent confidence interval, 2.50 to 9.80). While hormone therapy was not significantly associated with ECog-II total scores (b = −10.98; 95 percent confidence interval, −25.33 to 6.35), hormone therapy was significantly associated with lower MBIC total scores (b = −26.90; 95 percent confidence interval,−43.35 to −5.67).
"Menopausal symptom burden is associated with poorer cognitive function and more mild behavioral impairment symptoms in mid- to late-life. Hormone therapy may help mitigate symptoms of mild behavioral impairment," the authors write. "These findings suggest that the experience of menopause may indicate susceptibility to cognitive and behavioral changes, both markers of dementia."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.